Free Trial
NASDAQ:TRML

Tourmaline Bio Q1 2024 Earnings Report

Tourmaline Bio logo
$21.76 -0.37 (-1.67%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$21.80 +0.04 (+0.21%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tourmaline Bio EPS Results

Actual EPS
-$0.55
Consensus EPS
-$0.68
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Tourmaline Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tourmaline Bio Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Monday, May 13, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Tourmaline Bio's Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Tourmaline Bio Earnings Headlines

BMO Capital Remains a Buy on Tourmaline Bio (TRML)
Tourmaline Bio Inc News (TRML) - Investing.com
This Crypto Is Set to Explode in January
Free summit reveals where Bitcoin goes after $120k Don't miss this rare opportunity to learn directly from the experts who are driving this market…
TRML - Tourmaline Bio Inc Dividends - Morningstar
TRML - Tourmaline Bio Inc Executives - Morningstar
See More Tourmaline Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tourmaline Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tourmaline Bio and other key companies, straight to your email.

About Tourmaline Bio

Tourmaline Bio (NASDAQ:TRML) operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

View Tourmaline Bio Profile

More Earnings Resources from MarketBeat